SignatureFD’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.36K Sell
675
-80
-11% -$999 ﹤0.01% 2640
2025
Q4
$9.76K Sell
755
-133
-15% -$1.71K ﹤0.01% 2444
2025
Q3
$11.5K Sell
888
-74
-8% -$989 ﹤0.01% 2359
2025
Q2
$17.1K Sell
962
-399
-29% -$6.95K ﹤0.01% 2120
2025
Q1
$24.3K Buy
1,361
+130
+11% +$2.95K ﹤0.01% 1960
2024
Q4
$36.7K Sell
1,231
-48
-4% -$1.02K ﹤0.01% 1736
2024
Q3
$20K Sell
1,279
-365
-22% -$6.62K ﹤0.01% 2042
2024
Q2
$28.2K Buy
1,644
+627
+62% +$11K ﹤0.01% 1801
2024
Q1
$15.9K Buy
1,017
+201
+25% +$2.96K ﹤0.01% 2107
2023
Q4
$12.2K Buy
816
+106
+15% +$1.42K ﹤0.01% 2165
2023
Q3
$11.5K Buy
710
+182
+34% +$5.25K ﹤0.01% 2133
2023
Q2
$21.9K Sell
528
-352
-40% -$21.9K ﹤0.01% 1839
2023
Q1
$52.9K Sell
880
-92
-9% -$7.35K ﹤0.01% 1364
2022
Q4
$71.3K Sell
972
-76
-7% -$5.72K ﹤0.01% 1175
2022
Q3
$80K Sell
1,048
-507
-33% -$39.5K ﹤0.01% 1064
2022
Q2
$108K Buy
1,555
+180
+13% +$13.6K ﹤0.01% 953
2022
Q1
$114K Buy
1,375
+852
+163% +$62.8K ﹤0.01% 977
2021
Q4
$39K Buy
523
+197
+60% +$19.8K ﹤0.01% 1449
2021
Q3
$38K Sell
326
-119
-27% -$18K ﹤0.01% 1451
2021
Q2
$99K Buy
445
+60
+16% +$11.7K ﹤0.01% 961
2021
Q1
$51K Buy
385
+45
+13% +$7.12K ﹤0.01% 1164
2020
Q4
$59K Buy
340
+49
+17% +$6.71K ﹤0.01% 1001
2020
Q3
$32K Buy
291
+175
+151% +$14K ﹤0.01% 1173
2020
Q2
$7K Hold
116
﹤0.01% 1695
2020
Q1
$8K Buy
116
+101
+673% +$7.98K ﹤0.01% 1555
2019
Q4
$1K Buy
+15
New +$1.21K ﹤0.01% 2068

Other funds holding NVCR

SignatureFD's NVCR Position: Q1 2026 in Review

SignatureFD reduced its NovoCure (NVCR) stake by 11% in Q1 2026, selling an estimated $999 and leaving 675 shares worth $7.36K. The position accounts for ﹤0.01% of the portfolio, ranked #2640.

SignatureFD first reported a position in NVCR in Q4 2019 and has held it in 26 quarters since. The position peaked at $114K in Q1 2022. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • SignatureFD held 675 shares of NovoCure worth $7.36K as of Q1 2026.
  • SignatureFD sold 80 NovoCure shares in Q1 2026, an estimated $999.
  • NovoCure made up ﹤0.01% of SignatureFD's portfolio in Q1 2026, its #2640 holding.
  • SignatureFD first reported a position in NovoCure in Q4 2019 and has held it in 26 quarters since.
  • SignatureFD's NovoCure position peaked at $114K in Q1 2022.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on SignatureFD's 13F filing for Q1 2026, filed 7 Apr 2026.